Your joints, your diagnosis, a protocol built around both
Stem cell therapy for arthritis in Istanbul, Turkey
See how our Istanbul team matches osteoarthritis, rheumatoid, psoriatic, and crystal arthritis to the right cell therapy, dose, and aftercare plan.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Clinical map
Start with the diagnosis, stage, and treatment context
We confirm your exact diagnosis, joint, and disease activity before recommending any product, dose, or injection route.
Established care comes first
- We confirm the diagnosis first: History, examination, imaging, labs, and joint aspiration when needed — no protocol starts until we know exactly what we are treating.
- We treat the mechanism, not just the symptom: Exercise and load management for osteoarthritis, disease-modifying care for inflammatory disease, and urgent treatment for infection.
- We protect your function: Rehabilitation, pain management, and mobility support are built into your Istanbul plan alongside the cell therapy itself.
- 01
Osteoarthritis
Mechanical wear, cartilage loss, and joint alignment issues respond best to targeted, image-guided injections — we map each joint individually.
- 02
Inflammatory arthritis
Rheumatoid and psoriatic arthritis need systemic disease control first; our program is designed to complement, not replace, that care.
- 03
Crystal, infectious, and post-traumatic disease
Gout, pseudogout, infection, and old injuries get their own workup so we never treat the wrong problem.
Direct answer
What the current evidence says
Arthritis is not one disease, and it should not get one generic injection. Our physicians start with your exact diagnosis — osteoarthritis, rheumatoid, psoriatic, or crystal arthritis — then build a protocol around it: image-guided intra-articular MSC or exosome therapy for the right joint, a documented cell count and lab-tested product, and a plan that works alongside any disease-modifying medication you already need. Request a free medical evaluation and we will tell you plainly which joints and diagnoses respond best to what our program offers.
Evidence position
What is known, what is investigational, and what is not demonstrated
Diagnosis-led joint protocols
A hot, swollen joint, fever, or recent surgery is screened for infection first — that always comes before any cell therapy discussion.
We match the route to the diagnosis
If you have rheumatoid or psoriatic arthritis, we keep your disease-modifying therapy in place; our program supports your treatment, it does not replace it.
We tell you exactly what's in the syringe
We are upfront that results vary between patients and stem cell therapy is not a guaranteed cure — our focus is giving you the best-run protocol available.
Product and route
A mechanism is not a clinical outcome
- 01
We match the route to the diagnosis
A local injection result for one joint does not automatically apply to rheumatoid, psoriatic, or multi-joint arthritis — we explain what your product can realistically do.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
- 02
We tell you exactly what's in the syringe
Bone marrow concentrate, adipose tissue, culture-expanded MSCs, PRP, and exosomes are different products with different cell counts — your evaluation names the product before you travel.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
Evidence ledger
Read the actual study, including the result that did not change
Each row keeps product identity, route, endpoint, and limitation together so one trial cannot become a generic treatment claim.
01 ACR and Arthritis Foundation osteoarthritis guideline
Open source- Product
- Heterogeneous stem-cell injection preparations
- Route
- Intra-articular
- Design
- Evidence-based clinical practice guideline
- Finding
- The guideline recommends against stem-cell injections in knee and hip osteoarthritis because of heterogeneity and insufficient standardization.
- Limitation
- This statement is joint and evidence specific. It does not replace an individual diagnostic assessment.
Outcomes before travel
Decide what meaningful change would look like
A baseline and a time point matter more than an isolated testimonial. These measures should be chosen before any intervention.
- 01
Diagnosis-specific disease activity
- 02
Joint pain and function scale
- 03
Swelling, range of motion, and strength
- 04
Medication use and how you feel day to day
- 05
Imaging or lab follow-up when it adds value
Specialist review
What a complete Istanbul review needs
See how our Istanbul team matches osteoarthritis, rheumatoid, psoriatic, and crystal arthritis to the right cell therapy, dose, and aftercare plan.
Records and baseline
- Which joint or joints, symptom pattern, and how long you've had them
- Your rheumatology or orthopedic diagnosis and prior imaging
- Recent labs or aspiration results, if available
- Current medicines, injections, therapy, and how you've responded
- The exact product, joint target, guidance method, and dose we recommend for you
Safety and planning checks
- We never group all joint pain under one label or pick a route before we know your diagnosis.
- Keep taking any disease-modifying treatment unless your prescribing rheumatologist tells you otherwise.
- Your Istanbul plan lays out the experimental option next to the best established care for your exact diagnosis and joint, so you can choose with full information.
Transparent planning
Build the medical plan before the package
A quote should follow record review, product disclosure, route rationale, and a written follow-up plan. This page does not invent a universal price.
- We never group all joint pain under one label or pick a route before we know your diagnosis.
- Keep taking any disease-modifying treatment unless your prescribing rheumatologist tells you otherwise.
- Your Istanbul plan lays out the experimental option next to the best established care for your exact diagnosis and joint, so you can choose with full information.
Questions the plan must answer
- 01
We match the route to the diagnosis: A local injection result for one joint does not automatically apply to rheumatoid, psoriatic, or multi-joint arthritis — we explain what your product can realistically do.
- 02
We tell you exactly what's in the syringe: Bone marrow concentrate, adipose tissue, culture-expanded MSCs, PRP, and exosomes are different products with different cell counts — your evaluation names the product before you travel.
Primary reading
Guidelines, trials, and regulatory context
FAQ
Questions patients ask before an Istanbul review
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.